<?xml version='1.0' encoding='utf-8'?>
<document id="32237115"><sentence text="The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator."><entity charOffset="72-82" id="DDI-PubMed.32237115.s1.e0" text="Laquinimod" /></sentence><sentence text="Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod"><entity charOffset="0-10" id="DDI-PubMed.32237115.s2.e0" text="Laquinimod" /><entity charOffset="203-213" id="DDI-PubMed.32237115.s2.e1" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.32237115.s2.e0" e2="DDI-PubMed.32237115.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s2.e0" e2="DDI-PubMed.32237115.s2.e1" /></sentence><sentence text=" To determine the drug-drug interaction potential of laquinimod with CYP3A inhibitors and inducers, interaction assessments were conducted in healthy volunteers using single-dose administration of laquinimod before and after multiple dosing of CYP3A inhibitors (ketoconazole, fluconazole, and cimetidine) or a CYP3A4 inducer (rifampin)"><entity charOffset="53-63" id="DDI-PubMed.32237115.s3.e0" text="laquinimod" /><entity charOffset="197-207" id="DDI-PubMed.32237115.s3.e1" text="laquinimod" /><entity charOffset="262-274" id="DDI-PubMed.32237115.s3.e2" text="ketoconazole" /><entity charOffset="276-287" id="DDI-PubMed.32237115.s3.e3" text="fluconazole" /><entity charOffset="293-303" id="DDI-PubMed.32237115.s3.e4" text="cimetidine" /><entity charOffset="326-334" id="DDI-PubMed.32237115.s3.e5" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e0" e2="DDI-PubMed.32237115.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e0" e2="DDI-PubMed.32237115.s3.e1" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e0" e2="DDI-PubMed.32237115.s3.e2" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e0" e2="DDI-PubMed.32237115.s3.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e0" e2="DDI-PubMed.32237115.s3.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e0" e2="DDI-PubMed.32237115.s3.e5" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e1" e2="DDI-PubMed.32237115.s3.e1" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e1" e2="DDI-PubMed.32237115.s3.e2" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e1" e2="DDI-PubMed.32237115.s3.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e1" e2="DDI-PubMed.32237115.s3.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e1" e2="DDI-PubMed.32237115.s3.e5" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e2" e2="DDI-PubMed.32237115.s3.e2" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e2" e2="DDI-PubMed.32237115.s3.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e2" e2="DDI-PubMed.32237115.s3.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e2" e2="DDI-PubMed.32237115.s3.e5" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e3" e2="DDI-PubMed.32237115.s3.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e3" e2="DDI-PubMed.32237115.s3.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e3" e2="DDI-PubMed.32237115.s3.e5" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e4" e2="DDI-PubMed.32237115.s3.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s3.e4" e2="DDI-PubMed.32237115.s3.e5" /></sentence><sentence text=" For ketoconazole, subjects (n = 14) received laquinimod 0"><entity charOffset="5-17" id="DDI-PubMed.32237115.s4.e0" text="ketoconazole" /><entity charOffset="46-56" id="DDI-PubMed.32237115.s4.e1" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.32237115.s4.e0" e2="DDI-PubMed.32237115.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s4.e0" e2="DDI-PubMed.32237115.s4.e1" /></sentence><sentence text="6 mg following 1 day of ketoconazole (400 mg daily) pretreatment, a single concomitant dose, and 28 additional days"><entity charOffset="24-36" id="DDI-PubMed.32237115.s5.e0" text="ketoconazole" /></sentence><sentence text=" For fluconazole, subjects (n = 14) received laquinimod 0"><entity charOffset="5-16" id="DDI-PubMed.32237115.s6.e0" text="fluconazole" /><entity charOffset="45-55" id="DDI-PubMed.32237115.s6.e1" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.32237115.s6.e0" e2="DDI-PubMed.32237115.s6.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s6.e0" e2="DDI-PubMed.32237115.s6.e1" /></sentence><sentence text="6 mg after a single fluconazole dose of 400 mg followed by 200-mg daily fluconazole administration for 20 additional days"><entity charOffset="20-31" id="DDI-PubMed.32237115.s7.e0" text="fluconazole" /><entity charOffset="72-83" id="DDI-PubMed.32237115.s7.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.32237115.s7.e0" e2="DDI-PubMed.32237115.s7.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s7.e0" e2="DDI-PubMed.32237115.s7.e1" /></sentence><sentence text=" For cimetidine, subjects (n = 14) received laquinimod 0"><entity charOffset="5-15" id="DDI-PubMed.32237115.s8.e0" text="cimetidine" /><entity charOffset="44-54" id="DDI-PubMed.32237115.s8.e1" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.32237115.s8.e0" e2="DDI-PubMed.32237115.s8.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s8.e0" e2="DDI-PubMed.32237115.s8.e1" /></sentence><sentence text="6 mg following 1 day of cimetidine (800 mg twice daily) pretreatment, a single concomitant dose, and 21 additional days"><entity charOffset="24-34" id="DDI-PubMed.32237115.s9.e0" text="cimetidine" /></sentence><sentence text=" For rifampin, subjects (n = 14) received laquinimod 0"><entity charOffset="5-13" id="DDI-PubMed.32237115.s10.e0" text="rifampin" /><entity charOffset="42-52" id="DDI-PubMed.32237115.s10.e1" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.32237115.s10.e0" e2="DDI-PubMed.32237115.s10.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s10.e0" e2="DDI-PubMed.32237115.s10.e1" /></sentence><sentence text="6 mg following 9 days of rifampin (600 mg daily) pretreatment, a single concomitant dose, and 12 additional days"><entity charOffset="25-33" id="DDI-PubMed.32237115.s11.e0" text="rifampin" /></sentence><sentence text=" Coadministration of laquinimod with CYP3A inhibitors, ketoconazole, fluconazole, and cimetidine increased laquinimod area under the plasma concentration-time curve from time zero to infinity by approximately 3"><entity charOffset="21-31" id="DDI-PubMed.32237115.s12.e0" text="laquinimod" /><entity charOffset="55-67" id="DDI-PubMed.32237115.s12.e1" text="ketoconazole" /><entity charOffset="69-80" id="DDI-PubMed.32237115.s12.e2" text="fluconazole" /><entity charOffset="86-96" id="DDI-PubMed.32237115.s12.e3" text="cimetidine" /><entity charOffset="107-117" id="DDI-PubMed.32237115.s12.e4" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e0" e2="DDI-PubMed.32237115.s12.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e0" e2="DDI-PubMed.32237115.s12.e1" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e0" e2="DDI-PubMed.32237115.s12.e2" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e0" e2="DDI-PubMed.32237115.s12.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e0" e2="DDI-PubMed.32237115.s12.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e1" e2="DDI-PubMed.32237115.s12.e1" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e1" e2="DDI-PubMed.32237115.s12.e2" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e1" e2="DDI-PubMed.32237115.s12.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e1" e2="DDI-PubMed.32237115.s12.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e2" e2="DDI-PubMed.32237115.s12.e2" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e2" e2="DDI-PubMed.32237115.s12.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e2" e2="DDI-PubMed.32237115.s12.e4" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e3" e2="DDI-PubMed.32237115.s12.e3" /><pair ddi="false" e1="DDI-PubMed.32237115.s12.e3" e2="DDI-PubMed.32237115.s12.e4" /></sentence><sentence text="1-, 2" /><sentence text="5-, and 1" /><sentence text="1-fold, respectively" /><sentence text=" Coadministration of laquinimod with rifampin decreased laquinimod area under the plasma concentration-time curve from time zero to infinity by 5-fold"><entity charOffset="21-31" id="DDI-PubMed.32237115.s16.e0" text="laquinimod" /><entity charOffset="37-45" id="DDI-PubMed.32237115.s16.e1" text="rifampin" /><entity charOffset="56-66" id="DDI-PubMed.32237115.s16.e2" text="laquinimod" /><pair ddi="false" e1="DDI-PubMed.32237115.s16.e0" e2="DDI-PubMed.32237115.s16.e0" /><pair ddi="false" e1="DDI-PubMed.32237115.s16.e0" e2="DDI-PubMed.32237115.s16.e1" /><pair ddi="false" e1="DDI-PubMed.32237115.s16.e0" e2="DDI-PubMed.32237115.s16.e2" /><pair ddi="false" e1="DDI-PubMed.32237115.s16.e1" e2="DDI-PubMed.32237115.s16.e1" /><pair ddi="false" e1="DDI-PubMed.32237115.s16.e1" e2="DDI-PubMed.32237115.s16.e2" /></sentence><sentence text=" These results indicate that coadministration of laquinimod with moderate to strong inhibitors of CYP3A or strong inducers of CYP3A may give rise to significant pharmacokinetic drug interactions"><entity charOffset="49-59" id="DDI-PubMed.32237115.s17.e0" text="laquinimod" /></sentence><sentence text="" /></document>